Protocol · Treg · Apheresis · Hyperthermia
Chronic Lyme disease is not a single problem. It is a convergence of problems — active pathogen burden, accumulated inflammatory toxins, a dysregulated immune system, and a biological environment so hostile that any intervention applied to it faces significant obstacles from the other problems it hasn't addressed.
This is why single-modality treatment so often fails chronic Lyme patients. Antibiotics target the pathogen but leave the immune dysregulation and inflammatory burden untouched. Immune therapy operates in a system saturated with pro-inflammatory signals that undermine its effects. Anti-inflammatory approaches reduce symptoms temporarily without addressing what's producing them.
The combined protocol at the Lyme Immunotherapy Center addresses all three dimensions — pathogen burden, inflammatory load, and immune dysregulation — in a coordinated sequence specifically designed so each intervention amplifies the next. The result is a treatment effect that no single modality achieves alone.
To understand why the combined protocol is structured as it is, it helps to understand the three biological problems that need to be addressed simultaneously.
Active pathogen burden — Borrelia and co-infections that continue to drive immune activation, release bacterial antigens, and contribute to tissue inflammation. This is the initial trigger and, in many patients, an ongoing contributor to immune dysregulation even when bacterial load is low.
Accumulated inflammatory burden — pro-inflammatory cytokines, immune complexes, autoantibodies, and bacterial debris that have built up in the bloodstream over months or years of chronic inflammation. These molecules create a toxic internal environment that perpetuates immune overactivation regardless of current pathogen load.
Immune regulatory failure — the progressive depletion and dysfunction of T-Regulatory cells that has left the immune system without the capacity to govern its own responses. This is the mechanism that converts a resolving infection into a chronic, self-sustaining inflammatory condition.
Why addressing only one fails: Treating pathogen load alone leaves the dysregulated immune system and toxic inflammatory environment in place. Treating immune dysregulation alone leaves the pathogen and inflammatory burden to immediately undermine the new regulatory cells. The problems are entangled — they must be addressed together, in the right order.
Systemic Perfusion Hyperthermia comes first because it directly targets active Borrelia and co-infections at their most fundamental vulnerability — thermal tolerance. By raising core temperature to levels pathogens cannot sustain, SPH disrupts biofilm communities, impairs bacterial replication, and mobilizes heat-stressed organisms and their debris into circulation where subsequent interventions can address them. The goal at this phase is maximum pathogen stress before the environment is cleaned and regulated.
Therapeutic apheresis follows hyperthermia because SPH mobilizes inflammatory debris, bacterial fragments, and cytokines into circulation — and apheresis removes precisely these categories of molecules. The sequence is deliberate: hyperthermia creates the load, apheresis clears it. What remains is a dramatically reduced inflammatory burden — fewer pro-inflammatory cytokines, fewer immune complexes, a bloodstream significantly less hostile to the immune interventions that follow.
Autologous Treg infusion is positioned last because it operates most effectively in a clean environment — one where the inflammatory signals that would immediately destabilize newly introduced regulatory cells have been reduced. Reinfusing FOXP3-stabilized Tregs after apheresis has cleared the cytokine burden gives those cells the conditions they need to establish regulatory control. The immune system gets its governing mechanism back at the moment when the internal environment is most receptive to it.
Each intervention in the protocol creates conditions that make the next one more effective. This is not accidental — it is the central rationale for the combined approach.
The comprehensive 18-day program at the Lyme Immunotherapy Center integrates all three core interventions within a structured timeline, surrounded by supporting protocols that optimize each phase.
The first days of the program involve baseline evaluation, laboratory assessment, and preparatory IV protocols designed to optimize the patient's physiological state before the major interventions begin. This is not a holding period — it is a deliberate optimization phase that significantly affects the efficacy of what follows.
Systemic Perfusion Hyperthermia is performed in the hospital under full anesthesia and continuous monitoring, typically in the early portion of the protocol. Apheresis sessions follow, timed to capture the inflammatory burden mobilized by hyperthermia. Treg cell collection, processing, stress-test selection, expansion, and reinfusion occur across the middle and later portions of the program.
Throughout the 18 days, IV therapy protocols — antimicrobials, antioxidants, mitochondrial support, and immune modulators — provide continuous systemic support. Physiotherapy, nutritional guidance, and psychological support address the whole-person dimensions of recovery that purely biomedical treatment cannot.
The comprehensive 18-day program is designed for patients with significant, longstanding chronic Lyme disease — particularly those who have tried multiple approaches without lasting improvement. It is not appropriate for everyone, and the clinical evaluation prior to program enrollment is thorough.
Patients with active major cardiac conditions, severe uncontrolled comorbidities, or contraindications to any of the three core modalities may be better suited to one of our targeted single-modality programs — Treg therapy alone, or Apheresis combined with Hyperthermia — which address specific dimensions of the disease without the full 18-day protocol.
The decision about which program is appropriate is made individually, based on a comprehensive review of the patient's history, current condition, and treatment goals. No protocol is applied uniformly — every patient receives a program calibrated to their specific biology.
Our clinical team reviews each case individually to determine which program — and which sequence of interventions — best matches your history and goals.
Check My Eligibility